Description
Uses and Administration of Candesartan in Kenya
Candesartan is an angiotensin II receptor antagonist. It is used in the management of hypertension and has also been investigated in heart failure.
Candesartan is administered by mouth with the onset of its antihypertensive effect occuring about 2 hours after administration and the maximum effect being achieved within about 4 weeks after initiating therapy.
In the management of hypertension candesartan cilexetil is given in Kenya in an initial dose of 8 mg once daily, adjusted according to response. The usual maintenance dose is 8 mg once daily with a maximum dose of 16 mg once daily. In Kenya, higher doses are used; the usual initial dose is 16 mg once daily with a maintenance dose of 8 to 32 mg daily as a single dose or in two divided doses. Lower initial doses should be considered in patients with intravascular volume depletion; an initial dose of 4 mg once daily is suggested. Patients with renal or hepatic impairment may also require lower initial doses.
Adverse Effects of Candesartan
Adverse effects of Candesartan have been reported to be usually mild and transient, and include dizziness, headache, and dose-related orthostatic hypotension. Hypotension may occur particularly in patients with volume depletion (for example those who have received high-dose diuretics). Impaired renal function and, rarely, rash, urticaria, pruritus, angioedema, and raised liver enzyme values may occur. Hyperkalaemia, myalgia, and arthralgia have been reported. Other adverse effects of Candesartan that have been reported in Kenya include respiratory-tract disorders, back pain, gastrointestinal disturbances, fatigue, and neutropenia.
Reviews
There are no reviews yet.